New Frontiers in Pathology

Thursday, October 17, 2024, 7:30 AM - Friday, October 18, 2024, 4:00 PM EST, Graduate Hotel, Ann Arbor, MI


AMA PRA Category 1 Credits™ (12.50 hours), Non-Physician Attendance (12.50 hours)

This symposium is presented by the Department of Pathology, in conjunction with MLabs, and is intended to address the educational requirements for practicing pathologists, residents, and fellows. The impact of discoveries in molecular medicine and bioinformatics and the application of information technology to improve pathology practice are highlighted in plenary lectures and breakout sessions. Case-based presentations using virtual microscopy will address complex diagnostic challenges. At the end of this course, participants will have a better understanding of new methods of diagnosis using current tools and information technology and will be able to implement these in their daily practice.

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

For questions or concerns, please contact:
Shirley Hoffman
Brent Temple

Accessibility Statement
 
The University of Michigan Medical School is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008.  If you have needs that require special accommodations, including dietary concerns, please contact the CME Activity Coordinator.

Graduate Hotel
615 East Huron St
Ann Arbor, MI 48104

Mitigation of Relevant Financial Relationships

The University of Michigan Medical School adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners, or others are required to disclose all relevant financial relationships with ineligible entities. All relevant financial relationships have been mitigated prior to the commencement of the activity.